AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10960882 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 5 mg
Number of subjects: 0
Study 10960882 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 0
Study 10960882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8793795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresenius Polysulfone membrane
Number of subjects: 0
Study 8793795 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphen membrane
Number of subjects: 0
Study 8793795 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosulfane membrane
Number of subjects: 0
Study 1617039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 924
Study 1617039 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 924
Study 1617039 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 924
Study 1617039 — intervention group
Group type: COMPARATOR
Intervention: Cefixime
Number of subjects: 924
Study 6230950 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.2 mg/kg for muscle relaxation
Number of subjects: 40
Study 6230950 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 40
Study 30375234 — intervention group
Group type: EXPERIMENTAL
Intervention: SUNBEAM programme (strength and balance exercise programme)
Number of subjects: 221
Study 30375234 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 221
Study 30375234 — intervention group
Group type: EXPERIMENTAL
Intervention: SUNBEAM programme
Number of subjects: 221
Study 30375234 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 221
Study 29083530 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg/mL amphotericin B nasal irrigation
Number of subjects: 73
Study 29083530 — intervention group
Group type: COMPARATOR
Intervention: Normal saline irrigation
Number of subjects: 73
Study 29083530 — intervention group
Group type: COMPARATOR
Intervention: Comparison between AMB and saline
Number of subjects: 73
Study 24657218 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0
Study 24657218 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 22196782 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocedural sustained VT/VF
Number of subjects: 3485
Study 22196782 — intervention group
Group type: COMPARATOR
Intervention: Patients without postprocedural sustained VT/VF
Number of subjects: 3485
Study 19763604 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway (CP)
Number of subjects: 32
Study 19763604 — intervention group
Group type: COMPARATOR
Intervention: Control (no CP)
Number of subjects: 32
Study 18619793 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered mail
Number of subjects: 1550
Study 18619793 — intervention group
Group type: COMPARATOR
Intervention: Normal post
Number of subjects: 1550
Study 15675987 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous physostigmine infusion combined with morphine-based PCA
Number of subjects: 0
Study 15675987 — intervention group
Group type: COMPARATOR
Intervention: PCA alone
Number of subjects: 0
Study 12166337 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ramosetron intravenously
Number of subjects: 88
Study 12166337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 10381905 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg aspirin daily for 3 months
Number of subjects: 29
Study 10381905 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg aspirin daily for 3 months
Number of subjects: 29
Study 10381905 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg aspirin daily for 3 months
Number of subjects: 29
Study 8547651 — intervention group
Group type: EXPERIMENTAL
Intervention: High bcl-2 expression (found in 131 patients, 45%)
Number of subjects: 290
Study 8547651 — intervention group
Group type: COMPARATOR
Intervention: Negative/intermediate bcl-2 expression (94 patients, 32% negative and 94 patients with intermediate staining)
Number of subjects: 290
Study 8547651 — intervention group
Group type: EXPERIMENTAL
Intervention: High bcl-2 expression in diffuse large B-cell lymphoma (67 patients, 44%)
Number of subjects: 290
Study 1844773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (250 mg td) for 7 days
Number of subjects: 40
Study 1844773 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim sulfamethoxazole (160/800 mg td) for 7 days
Number of subjects: 40
Study 6557966 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Fenoterol orally before 0.4 mg PGE2 gel
Number of subjects: 26
Study 6557966 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg PGE2 gel
Number of subjects: 26
Study 6557966 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg PGE2 gel
Number of subjects: 26
Study 6557966 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 26
Study 30972702 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 361
Study 30972702 — intervention group
Group type: COMPARATOR
Intervention: Investigator's Choice (IC)
Number of subjects: 361
Study 29164902 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolised clinical intervention plus usual care (n = 64)
Number of subjects: 127
Study 29164902 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (n = 63)
Number of subjects: 127
Study 26762497 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate with Opsite (G+O)
Number of subjects: 211
Study 26762497 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate with Tegaderm (G+T)
Number of subjects: 211
Study 26762497 — intervention group
Group type: COMPARATOR
Intervention: Opsite without 2-octyl cyanoacrylate (O)
Number of subjects: 211
Study 26762497 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison across all groups
Number of subjects: 211
Study 24622803 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 737
Study 24622803 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet
Number of subjects: 737
Study 24622803 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight regain from 6 to 24 months
Number of subjects: 737
Study 24622803 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intakes
Number of subjects: 737
Study 21415284 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1200 mg
Number of subjects: 67
Study 21415284 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 2400 mg
Number of subjects: 67
Study 21415284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 21415284 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (single dose)
Number of subjects: 67
Study 19328257 — intervention group
Group type: EXPERIMENTAL
Intervention: Underreporting detection methods
Number of subjects: 357
Study 19328257 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight status (overweight and obese)
Number of subjects: 357
Study 19328257 — intervention group
Group type: EXPERIMENTAL
Intervention: Anglo orientation score
Number of subjects: 357
Study 19328257 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group of 51 years or older
Number of subjects: 357
Study 17993728 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition
Number of subjects: 41
Study 17993728 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition
Number of subjects: 41
Study 15379365 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/DRSP (30 microg ethinyl estradiol and 3 mg drospirenone)
Number of subjects: 1154
Study 15379365 — intervention group
Group type: COMPARATOR
Intervention: EE/NGM (35 microg ethinyl estradiol and 0.180, 0.215, 0.250 mg norgestimate)
Number of subjects: 1154
Study 15379365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 1154
Study 11307411 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted therapy (diode laser light, 1-watt output, maximum of 20 seconds)
Number of subjects: 50
Study 11307411 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 50
Study 9381042 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin monotherapy
Number of subjects: 0
Study 9381042 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 0
Study 8398517 — intervention group
Group type: EXPERIMENTAL
Intervention: Amethocaine patch (30-min application)
Number of subjects: 0
Study 8398517 — intervention group
Group type: EXPERIMENTAL
Intervention: Amethocaine patch (60-min application)
Number of subjects: 0
Study 8398517 — intervention group
Group type: COMPARATOR
Intervention: EMLA (60-min application)
Number of subjects: 0
Study 8398517 — intervention group
Group type: COMPARATOR
Intervention: Amethocaine gel preparation
Number of subjects: 0
Study 3943382 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO) at 3 Hz, maximal pressure (90 to 102 cm H2O)
Number of subjects: 5
Study 3943382 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO) at 3 Hz, half-maximal pressure
Number of subjects: 5
Study 3943382 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO) at 5 Hz, maximal pressure
Number of subjects: 5
Study 3943382 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO) at 5 Hz, half-maximal pressure
Number of subjects: 5
Study 3943382 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO) at 8 Hz, maximal pressure
Number of subjects: 5
Study 3943382 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO) at 8 Hz, half-maximal pressure
Number of subjects: 5
Study 3943382 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO) at 3 Hz, maximal pressure
Number of subjects: 5
Study 3338251 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebreathing a 2% CO mixture
Number of subjects: 0
Study 3338251 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-hold CO
Number of subjects: 0
Study 3338251 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean alveolar CO
Number of subjects: 0
Study 3338251 — intervention group
Group type: COMPARATOR
Intervention: Breath-hold and rebreathing CO
Number of subjects: 0
Study 3338251 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-hold and mean alveolar CO
Number of subjects: 0
Study 31218964 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 80
Study 31218964 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (placebo)
Number of subjects: 80
Study 28728744 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta Blocker (BB) use at ≥50% target dose
Number of subjects: 129
Study 28728744 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in heart rate (HR) by 10 beats/min
Number of subjects: 129
Study 25789519 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy (2.0 mg of 17β‐estradiol)
Number of subjects: 99
Study 25789519 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen‐progestin therapy (2.0 mg of 17 β‐estradiol + 1.0 mg of norethisterone acetate)
Number of subjects: 99
Study 25789519 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 99
Study 23743559 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon (IFN) α‐2b plus ribavirin for 16 weeks
Number of subjects: 130
Study 23743559 — intervention group
Group type: COMPARATOR
Intervention: Pegylated-interferon (IFN) α‐2b plus ribavirin for 24 weeks
Number of subjects: 130
Study 23743559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis for 16 weeks treatment
Number of subjects: 130
Study 23743559 — intervention group
Group type: COMPARATOR
Intervention: Cost analysis for 24 weeks treatment
Number of subjects: 130
Study 21930798 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 792
Study 19451304 — intervention group
Group type: EXPERIMENTAL
Intervention: KBPA-101 at 0.1 mg/kg
Number of subjects: 32
Study 19451304 — intervention group
Group type: EXPERIMENTAL
Intervention: KBPA-101 at 0.4 mg/kg
Number of subjects: 32
Study 19451304 — intervention group
Group type: EXPERIMENTAL
Intervention: KBPA-101 at 1.2 mg/kg
Number of subjects: 32
Study 19451304 — intervention group
Group type: EXPERIMENTAL
Intervention: KBPA-101 at 4.0 mg/kg
Number of subjects: 32
Study 19451304 — intervention group
Group type: EXPERIMENTAL
Intervention: KBPA-101
Number of subjects: 32
Study 16549451 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of labeled zinc (67Zn) with 50 mg AA (LoZn group)
Number of subjects: 75
Study 16549451 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of labeled zinc (67Zn) with 50 mg AA (HiZn group)
Number of subjects: 75
Study 16549451 — intervention group
Group type: COMPARATOR
Intervention: 5 mg zinc with no AA (control)
Number of subjects: 75
Study 15286543 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing (ODD) of tobramycin (7 mg/kg)
Number of subjects: 58
Study 15286543 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily dosing (MDD) of tobramycin
Number of subjects: 58
Study 11130626 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention program
Number of subjects: 0
Study 11130626 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 9331215 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 15 microg/ml twice daily
Number of subjects: 50
Study 9331215 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 50 microg/ml once daily
Number of subjects: 50
Study 8226140 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy to doses of 60.0 Gy, 64.8 Gy, 69.6 Gy, 74.4 Gy, or 79.2 Gy, 1.2 Gy twice daily, 5 days per week.
Number of subjects: 1244
Study 8226140 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy with deviations in treatment time.
Number of subjects: 1244
Study 8226140 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation (55-60 Gy in 30 fractions).
Number of subjects: 1244
Study 8226140 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation (69.6 Gy or higher).
Number of subjects: 1244
Study 2418902 — intervention group
Group type: EXPERIMENTAL
Intervention: Permixon (160 mg bd)
Number of subjects: 0
Study 2418902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31679465 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week low-energy diet before total knee replacement
Number of subjects: 76
Study 31679465 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 76
Study 29596150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (24 international units)
Number of subjects: 27
Study 29596150 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 27
Study 25497998 — intervention group
Group type: EXPERIMENTAL
Intervention: EPG 10 g/day
Number of subjects: 139
Study 25497998 — intervention group
Group type: EXPERIMENTAL
Intervention: EPG 25 g/day
Number of subjects: 139
Study 25497998 — intervention group
Group type: EXPERIMENTAL
Intervention: EPG 40 g/day
Number of subjects: 139
Study 25497998 — intervention group
Group type: COMPARATOR
Intervention: Margarine alone (control)
Number of subjects: 139
Study 21347608 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (gel)
Number of subjects: 38
Study 20157843 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (TT) - warfarin, ASA, and clopidogrel
Number of subjects: 20
Study 20157843 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (DT) - ASA and clopidogrel
Number of subjects: 20
Study 19114376 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose (1 mg/kg) MTW
Number of subjects: 45
Study 19114376 — intervention group
Group type: EXPERIMENTAL
Intervention: Half dose (0.5 mg/kg) MTW
Number of subjects: 45
Study 19114376 — intervention group
Group type: COMPARATOR
Intervention: Control (no MTW)
Number of subjects: 45
Study 15825548 — intervention group
Group type: EXPERIMENTAL
Intervention: Repinotan 0.5 mg/day
Number of subjects: 240
Study 15825548 — intervention group
Group type: EXPERIMENTAL
Intervention: Repinotan 1.25 mg/day
Number of subjects: 240
Study 15825548 — intervention group
Group type: EXPERIMENTAL
Intervention: Repinotan 2.5 mg/day
Number of subjects: 240
Study 15825548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 12861157 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine vaginal irrigation (200 mL of 0.2% chlorhexidine solution every 6 hours during labor)
Number of subjects: 1041
Study 12861157 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile saline solution every 6 hours during labor)
Number of subjects: 1041
Study 10868308 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam syrup (0.25, 0.5, or 1.0 mg/kg)
Number of subjects: 85
Study 10868308 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam syrup (0.25 to 1.0 mg/kg)
Number of subjects: 85
Study 10868308 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam syrup (1.0 mg/kg)
Number of subjects: 85
Study 9207619 — intervention group
Group type: EXPERIMENTAL
Intervention: Dig WD Mild (withdrawn from digoxin)
Number of subjects: 0
Study 9207619 — intervention group
Group type: EXPERIMENTAL
Intervention: Dig WD Moderate (withdrawn from digoxin)
Number of subjects: 0
Study 9207619 — intervention group
Group type: COMPARATOR
Intervention: Dig Cont (continued receiving digoxin)
Number of subjects: 0
Study 8451491 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85 BV
Number of subjects: 291
Study 8451491 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 291
Study 3085906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirbuterol
Number of subjects: 7
Study 3085906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29888566 — intervention group
Group type: EXPERIMENTAL
Intervention: Tender-point needling at SP 6, SP 8, and SP 9
Number of subjects: 72
Study 29888566 — intervention group
Group type: COMPARATOR
Intervention: Regular acupoint needling at SP 6, SP 8, and SP 9
Number of subjects: 72
Study 27875025 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsufflation (15 minutes, twice daily)
Number of subjects: 18
Study 25230593 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold (Absorb, Abbott Vascular)
Number of subjects: 501
Study 25230593 — intervention group
Group type: COMPARATOR
Intervention: Metallic stent (Xience, Abbott Vascular)
Number of subjects: 501
Study 22951078 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal switch
Number of subjects: 60
Study 22951078 — intervention group
Group type: COMPARATOR
Intervention: Gastric bypass
Number of subjects: 60
Study 22951078 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 21998053 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 1224
Study 21998053 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1224
Study 18155811 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intradermal (ID) BCG and Hepatitis B (HbsAg 10 microg plus BCG suspension 0.1mg)
Number of subjects: 0
Study 18155811 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) Hepatitis B
Number of subjects: 0
Study 16446025 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban intravenously (n=31)
Number of subjects: 63
Study 16446025 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine orally (n=32)
Number of subjects: 63
Study 14600063 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session intervention group
Number of subjects: 360
Study 14600063 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session intervention group
Number of subjects: 360
Study 14600063 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 360
Study 10817849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate+ (patients using nitrate-containing drugs)
Number of subjects: 40
Study 10817849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate- (patients not using nitrate-containing drugs)
Number of subjects: 40
Study 10817849 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CHF (group 2)
Number of subjects: 40
Study 10817849 — intervention group
Group type: COMPARATOR
Intervention: Patients with CHF (all groups)
Number of subjects: 40
Study 10817849 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CHF (group 1)
Number of subjects: 40
Study 10817849 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CHF
Number of subjects: 40
Study 8911839 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fentanyl anaesthesia + thoracic epidural analgesia
Number of subjects: 54
Study 8911839 — intervention group
Group type: COMPARATOR
Intervention: High-dose fentanyl anaesthesia
Number of subjects: 54
Study 1687200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ismo-Retard 40 mg
Number of subjects: 44
Study 1687200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ismo-Retard 40 mg (15 consecutive once-daily doses)
Number of subjects: 44
Study 1687200 — intervention group
Group type: EXPERIMENTAL
Intervention: Imdur 60 mg
Number of subjects: 44
Study 1687200 — intervention group
Group type: EXPERIMENTAL
Intervention: Imdur 60 mg (15 consecutive once-daily doses)
Number of subjects: 44
Study 6637313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of indomethacin (Confortid) 50 mg
Number of subjects: 50
Study 6637313 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of 2 mg hydromorphine chloride-atropine (Dilaudid-atropin 1 ml) with a suppository of prochlorperazine (Stemetil) 25 mg
Number of subjects: 50
Study 30952748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination
Number of subjects: 101
Study 30952748 — intervention group
Group type: COMPARATOR
Intervention: Standard Temozolomide-based therapy
Number of subjects: 101
Study 29068935 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthognathic surgery
Number of subjects: 20
Study 25915048 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 5881